Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03937791 · FLOW

Participant flow

Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions · Source last updated 2021-04-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
    id
    FG000
    title
    Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    1x10\^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0. E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
    id
    FG000
    title
    Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice